Moderna experienced strong upward momentum following continued enthusiasm over its high-profile oncology pipeline. Investors responded positively to news that Phase 3 INTerpath-001 trial data for intismeran autogene, its investigational mRNA-based personalized cancer therapy co-developed with Merck, was selected for a late-breaking Presidential Symposium presentation at the upcoming European Society for Medical Oncology Congress. The market views this prestigious presentation slot as a strong signal of clinical validation for the adjuvant melanoma treatment, bolstering investor confidence in the company’s ability to successfully expand beyond its core infectious disease business.

Compounding the positive sentiment, recent regulatory…